23309-90-2

Basic information

• Product Name: 1-(1,2,3,4-tetrahydroacridin-9-yl)triaza-1,2-dien-2-ium
• CAS NO: 23309-90-2
• Molecular Formula: C₁₃H₁₃N₄
• Molecular Weight: 225.2686
• Mol File: 23309-90-2.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1-(1,2,3,4-tetrahydroacridin-9-yl)triaza-1,2-dien-2-ium(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(1,2,3,4-tetrahydroacridin-9-yl)triaza-1,2-dien-2-ium(23309-90-2)
• EPA Substance Registry System: 1-(1,2,3,4-tetrahydroacridin-9-yl)triaza-1,2-dien-2-ium(23309-90-2)

Safety Data

• Hazardous Substances Data: 23309-90-2(Hazardous Substances Data)

Usage

Description

1-(1,2,3,4-tetrahydroacridin-9-yl)triaza-1,2-dien-2-ium is a chemical compound featuring a heterocyclic structure with a triaza-dien-2-ium moiety attached to a tetrahydroacridine ring. This unique structure suggests potential pharmaceutical applications and biological activities, making it a compound of interest for further investigation in the fields of pharmaceuticals and medical research.

Uses

Used in Pharmaceutical Applications:
1-(1,2,3,4-tetrahydroacridin-9-yl)triaza-1,2-dien-2-ium is used as a potential pharmaceutical agent for its unique structure and potential biological activities. 1-(1,2,3,4-tetrahydroacridin-9-yl)triaza-1,2-dien-2-ium's specific properties and uses require further study and evaluation, but its structure indicates possible interactions with biological systems and medicinal effects.
Used in Medical Research:
In the field of medical research, 1-(1,2,3,4-tetrahydroacridin-9-yl)triaza-1,2-dien-2-ium is used as a subject of investigation for its chemical and biological properties. 1-(1,2,3,4-tetrahydroacridin-9-yl)triaza-1,2-dien-2-ium's potential applications in pharmaceuticals or other medical areas are of significant interest, warranting further exploration and experimentation.

Upstream product

• 5396-30-5 9-chloro-1,2,3,4-tetrahydroacridine 
• 65197-50-4 cloridrato della 1,2,3,4-tetraidro-9-idrazinoacridina 

Relevant articles and documents

Rational design and biological evaluation of a new class of thiazolopyridyl tetrahydroacridines as cholinesterase and GSK-3 dual inhibitors for Alzheimer's disease

A key factor in the success of the MTDLs drug discovery approach is the selection of suitable target proteins. Based on the results of our previous research regarding dual-target inhibitors of AChE/GSK-3β and analysis of target proteins, in the current study, 28 hybrids were designed and synthesized. Docking studies allowed us to rationalize the binding mode of the synthesized compounds in both targets. In vitro enzyme inhibition studies identified compound GT15 as a lead molecule with preferential AChE/GSK-3β inhibition (hAChE IC50 = 1.2 ± 0.1 nM; hGSK-3β IC50 = 22.2 ± 1.4 nM). In addition, GT15 showed high kinase selectivity for GSK-3, except for DYRK1, with inhibition rate of 83.69% and 67.94% against DYRK1α and DYRK1β at a concentration of 20 μM. The compound also exhibited good permeability across the blood-brain-barrier and ability to inhibit the phosphorylation of tau protein. Upon oral administration, GT15 exhibited promising cognitive improvement in the scopolamine-induced cognitive deficit mice in the Morris water maze model. These results suggest that AChE and GSK-3 based multitargeted approach have therapeutic potential for Alzheimer's disease.

Synthesis of 4-quinolylazide derivatives and evaluation of their antitumor and antimicrobial activity

Synthesis and pharmacological evaluation of a series of 4-quinolylazide derivatives are reported. These were screened against P388 lymphocitic leukemia in mice, but they resulted inactive. All the compounds were also tested for their antimicrobial activity against gram-positive, gram-negative strains and fungi; only three derivatives exhibited poor activity.